Antiphospholipid antibody levels in intravenous immunoglobulin (IVIg) preparations

被引：13

作者：

Sherer, Y

Wu, R

Krause, I

Peter, JB

Shoenfeld, Y ^{[1
]}

机构：

[1] Chaim Sheba Med Ctr, Dept Med B, IL-52621 Tel Hashomer, Israel

[2] Chaim Sheba Med Ctr, Ctr Autoimmune Dis, IL-52621 Tel Hashomer, Israel

[3] Tel Aviv Univ, Sackler Fac Med, IL-69978 Tel Aviv, Israel

[4] Specialty Lab, Santa Monica, CA USA

来源：

LUPUS | 2001年 / 10卷 / 08期

关键词：

anti-cardiolipin antibody; antiphospholipid syndrome; beta; 2-glycoprotein-I; intravenous immunoglobulin;

D O I：

10.1191/096120301701549705

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

The antiphospholipid syndrome (APS) is characterized by various clinical manifestations and by elevated levels of antiphospholipid antibodies. Passive induction of APS by infusion of these antibodies has been demonstrated in animal models. Intravenous immunoglobulin (IVIg) is one of the therapeutic options in APS. In this study, five commercially used preparations of IVIg were tested for the presence of elevated levels of cardiolipin, beta -glycoprotein-1, phosphatidylserine, antinuclear, and double-stranded DNA autoantibodies, as well as for lupus anticoagulant activity. The absence of abnormal elevated levels of any of these autoantibodies in five different IVIg preparations provides additional evidence for the safety of IVIg use in APS.

引用

页码：568 / 570

页数：3

共 11 条

[1] INDUCTION OF ANTIPHOSPHOLIPID SYNDROME IN NAIVE MICE WITH MOUSE LUPUS MONOCLONAL AND HUMAN POLYCLONAL ANTICARDIOLIPIN ANTIBODIES [J].